| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05df9bb5afc09dcaa19f4102006bc58b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a7ebd2ce5ef7e691bd44c48a88a2bfc |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2018-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e95dd81201089774525e4731e4983c2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_203fab7325a732368bc957f1a07e3af4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ccf19b4345f7c98441bad70af4d024a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1eb52d44c8c3de19c4ad07f6b4c43120
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_021b7088d7b2019e303ae314551628c5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eddd5fe9475f71aafeb974709cb375c4 |
| publicationDate |
2018-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2018209017-A1 |
| titleOfInvention |
Cancer treatment with a cxcl12 signaling inhibitor and an immune checkpoint inhibitor |
| abstract |
The present invention relates to methods and compositions for treating cancer and enhancing the immune response against cancer cells using the combination of an inhibitor of CXCL12 signaling and an immune checkpoint inhibitor. The invention further relates to compositions and kits of parts comprising an inhibitor of CXCL 12 signaling and an immune checkpoint inhibitor for use in the methods of the invention. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022032091-A1 |
| priorityDate |
2017-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |